RT Journal Article
SR Electronic
T1 A rapid and cost-effective multiplex ARMS-PCR method for the simultaneous genotyping of the circulating SARS-CoV-2 phylogenetic clades
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.08.20209692
DO 10.1101/2020.10.08.20209692
A1 Islam, Md. Tanvir
A1 Alam, A. S. M. Rubayet Ul
A1 Sakib, Najmuj
A1 Hasan, Md. Shazid
A1 Chakrovarty, Tanay
A1 Tawyabur, Md.
A1 Islam, Ovinu Kibria
A1 Al-Emran, Hassan M.
A1 Jahid, Iqbal Kabir
A1 Hossain, M. Anwar
YR 2020
UL http://medrxiv.org/content/early/2020/10/13/2020.10.08.20209692.abstract
AB Tracing the globally circulating SARS-CoV-2 mutants is essential for the outbreak alerts and far-reaching epidemiological surveillance. The available technique to identify the phylogenetic clades through high-throughput sequencing is costly, time-consuming, and labor-intensive that hinders the viral genotyping in low-income countries. Here, we propose a rapid, simple and cost-effective amplification-refractory mutation system (ARMS)-based multiplex reverse-transcriptase PCR assay to identify six distinct phylogenetic clades: S, L, V, G, GH, and GR. This approach is applied on 24 COVID-19 positive samples as confirmed by CDC approved real-time PCR assay for SARS-CoV-2. Our multiplex PCR is designed in a mutually exclusive way to identify V-S and G-GH-GR clade variants separately. The pentaplex assay included all five variants and the quadruplex comprised of the triplex variants alongside either V or S clade mutations that created two separate subsets. The procedure was optimized in the primer concentration (0.2-0.6 µM) and annealing temperature (56-60°C) of PCR using 3-5 ng/µl cDNA template synthesized upon random- and oligo(dT)-primer based reverse transcription. The different primer concentration for the triplex and quadruplex adjusted to different strengths ensured an even amplification with a maximum resolution of all targeted amplicons. The targeted Sanger sequencing further confirmed the presence of the clade-featured mutations with another set of our designed primers. This multiplex ARMS-PCR assay is sample, cost-effective, and convenient that can successfully discriminate the circulating phylogenetic clades of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialWe conducted a study with the RNA of the leftover viral samples and hence it doesn't require clinical trial.Funding StatementThe present study was funded by Jashore University of Science and Technology research grant (#FoBST-06) supported by University Grant Commission, Bangladesh.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethical review committee of Jashore University of Science and Technology (Ref: ERC/FBS/JUST/2020-45, Date: 06/10/2020). The samples have been used from the routine diagnosis.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData can be checked from the GISAID EpiFlu database and the accession numbers are EPI_ISL_548260, EPI_ISL_561630, EPI_ISL_561375, EPI_ISL_561376 and EPI_ISL_561377.